---
title: "TCRX: In vivo TCR therapies for solid tumors advance to IND-enabling stage, with phase I trial set for Q4 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297802700.md"
description: "Two in vivo TCR therapies for solid tumors have advanced to IND-enabling activities, with preclinical data and regulatory updates expected in Q1 2027 and a phase I trial planned for Q4 2027. The heme malignancy program showed strong early results but is paused pending partnerships, while the autoimmune program is also on hold. Financial runway now extends to Q4 2027.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-09-02T14:39:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297802700.md)
  - [en](https://longbridge.com/en/news/297802700.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297802700.md)
generator: "portal-rs"
---

# TCRX: In vivo TCR therapies for solid tumors advance to IND-enabling stage, with phase I trial set for Q4 2027

Two in vivo TCR therapies for solid tumors have advanced to IND-enabling activities, with preclinical data and regulatory updates expected in Q1 2027 and a phase I trial planned for Q4 2027. The heme malignancy program showed strong early results but is paused pending partnerships, while the autoimmune program is also on hold. Financial runway now extends to Q4 2027.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [TCRX.US](https://longbridge.com/en/quote/TCRX.US.md)

## Related News & Research

- [TCRX: Focus shifts to in vivo TCR-T solid tumor therapies, with two candidates advancing to clinical studies](https://longbridge.com/en/news/297776068.md)
- [TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction](https://longbridge.com/en/news/297808078.md)
- [What the West misses when it judges Chinaâs dogged AI pursuit](https://longbridge.com/en/news/300214004.md)
- [TScan Therapeutics cuts workforce 75% in reorganization to focus on in vivo solid tumor cell therapy](https://longbridge.com/en/news/297773935.md)
- [TCRX: TSC-101 showed 79% relapse-free survival at 6 months in high-risk post-HCT patients](https://longbridge.com/en/news/297781448.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**